Key facts: €208M Q3 free cash flow; €0.15 interim dividend approved
Grifols (GRF) reported €208M in Q3 2026 free cash flow, with nine-month cash flow up €110M year over year. The company approved a €0.15 interim dividend per share, payable December 4.
How this was made

The 30-second read
Why it matters
The disclosed cash flow and dividend provide fresh data for valuation models and may trigger short-term buying.
Market read
New dividend and cash flow figures give traders a concrete catalyst for short-term positioning.
What to watch
Potential tax implications of the dividend for ADR holders and upcoming earnings guidance.
Background
Grifols is a Spanish pharmaceutical firm listed in the US as an ADR (GRF). The company regularly issues interim dividends.
Ticker impact
Grifols reported €208M Q3 free cash flow and approved a €0.15 interim dividend, new corporate action disclosed today.
modest upside as investors price in the dividend and cash generation
Dividend announcements typically lift the share price modestly, especially when accompanied by solid cash flow.
Market effects
Positive signal for the healthcare/pharma sector's cash generation trends.
May provide slight support to European biotech stocks.
Limited to investors tracking dividend yields and cash flow metrics.
Counterpoint
If the dividend is seen as insufficient relative to cash flow, the stock could face pressure.
Key entities
- companyGrifols
Spanish pharma firm, US ADR ticker GRF.

